Navigation Links
Novel monoclonal antibody offers potential treatment for tumors resistant to VEGF therapy
Date:11/13/2011

SAN FRANCISCO Despite the widespread use of current antiangiogenic cancer therapies, many tumors escape this blockade, which is designed to shut down growth of new blood vessels that feed tumors and spread cancer cells. Now, a study reported at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics suggests that targeting a novel antiangiogenic receptor may help patients whose cancer does not respond to existing agents.

The experimental agent, PF-03446962, targets activin receptor-like kinase 1 (ALK-1), which is part of the transforming growth factor (TGF) superfamily of receptors that potentially regulate cell growth and differentiation. Known as a tumor suppressor, TGF can conversely promote invasion and metastasis during the later stages of cancer progression, said Filippo de Braud, M.D., who was director of new drugs at the European Institute of Oncology when the study was conducted and is now chief of the Medical Oncology Department at the National Tumor Institute in Milan, Italy.

Tumor cells frequently lose the growth inhibitory response to TGF, which makes it a prime target for cancer treatment, he said. PF-03446962, a fully humanized monoclonal antibody, specifically inhibits the activity of ALK-1, which the researchers said is in part regulated by vascular endothelial growth factor (VEGF), the protein that activates angiogenesis and other proangiogenic factors. Shutting down ALK-1 inhibits the VEGF pathway in a manner different from other antiangiogenic treatments now on the market, de Braud said.

Researchers tested PF-03446962 in a phase 1 clinical trial, which demonstrated that the agent exerted anticancer activity in tumors already resistant to VEGF treatment.

De Braud and his colleagues tested eight different doses of PF-03446962 in 44 patients with solid tumors. Results showed a partial response in three patients and stable disease lasting at least four months in seven patient
'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Benefit of novel drug in breast cancer seen in blood within weeks
2. Novel technique switches triple-negative breast cancer cells to hormone-receptor positive cells
3. The Michael J. Fox Foundation awards nearly $200,000 to develop novel drugs for Parkinsons disease
4. Novel technique uses RNA interference to block inflammation
5. La Jolla Institute discovers novel mechanism for preventing infection via bodys mucosal borders
6. Novel drug combination offers therapeutic promise for hard-to-treat cancers
7. Novel approach scores first success against elusive cancer gene
8. Novel method for increasing antibiotic yields
9. Tropical coral could be used to create novel sunscreens for human use, say scientists
10. A novel mechanism that regulates pro-inflammatory cells is identified
11. Novel analysis by Allen Institute sheds new light on the mechanisms of brain development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 16, 2014  Automation is fundamentally transforming ... evident than at international borders. Over the past ... have allowed veteran travelers to self process through ... (APC) Kiosks at an increasing number of airports, ... According to Maxine Most , ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... Enerbck, Professor at the Institute of Biomedicine at the Sahlgrenska ... who published their results in The New England Journal ... and others show that adults use brown fat to convert ... possibilities in treating overweight and obesity. It has previously ...
... not for a group of enzymes called topoisomerases, DNA ... a cell as it gets twisted, rolled, unzipped, and ... its sequence. Topoisomerases, which are responsible for relieving ... were first discovered in the 1970s by Harvard,s Professor ...
... the Monell Center report that the red panda is the ... sweetener aspartame. This unexpected affinity for an artificial sweetener ... receptor. The findings may shed light on ... differences in taste receptors. "The red panda,s unique taste ...
Cached Biology News:New book, 'Untangling the Double Helix,' explores enzymes responsible for maintaining genome integrity 2Red pandas reveal an unexpected (artificial) sweet tooth 2Red pandas reveal an unexpected (artificial) sweet tooth 3
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... , , Nursing Care at Hahnemann ... 16 Hahnemann University Hospital proudly announces it has been ... Magnet Recognition Program(R). Magnet(R) is one of the highest levels ... places Hahnemann among the five percent of hospitals in the ...
... , Toronto biotechnology company,s revenues increase 22% ... in fiscal 2010 , TORONTO, Dec. 16 /PRNewswire-FirstCall/ - ... virology and biological technologies, today reported financial results for ... ended September 30, 2009, Microbix reported revenues of $6.08 ...
... ... Soy Peptone. HSP A has been found to be effectinve in improving yelds of ... (PRWEB) December ... Peptones by introducing HSP-A Soy Peptone. HSP-A, previously manufactured by Nutricepts, Inc. (Burnsville, Mn), ...
Cached Biology Technology:Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3Microbix' Pipeline Set To Reach Milestones In 2010 2Microbix' Pipeline Set To Reach Milestones In 2010 3Microbix' Pipeline Set To Reach Milestones In 2010 4Microbix' Pipeline Set To Reach Milestones In 2010 5Microbix' Pipeline Set To Reach Milestones In 2010 6Microbix' Pipeline Set To Reach Milestones In 2010 7Microbix' Pipeline Set To Reach Milestones In 2010 8
... between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) ... the lumenal surface of endothelial cells at ... primary role of PSGL-1 in mediating the ... well documented.MAB4092 completely blocks recognition of PSGL-1 ...
Mouse Anti-Human MCAF-(MCP-1)...
Mouse VEGF R1/Flt-1 Phycoerythrin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
Biology Products: